BPMC — Blueprint Medicines Share News
0.000.00%
Last trade - 00:00- $8.37bn
- $8.18bn
- $508.82m
U.S. STOCKS ON THE MOVE-Yelp, Shutterstock, TCS
Blueprint Medicines up on rare disorder drug approval, brokerages raise PTs
Brief: FDA Approves Ayvakit As First Treatment For Indolent Systemic Mastocytosis
U.S. RESEARCH ROUNDUP-Albemarle, Cable One, Southwest Airlines
U.S. RESEARCH ROUNDUP-Iveric Bio, Booking Holdings, Netscout Systems
Blueprint Medicines Corp reports results for the quarter ended in March - Earnings Summary
Brief: Blueprint Medicines Reports First Quarter 2023 Results
Brief: Blueprint Medicines posts Q1 revenue USD 63.3 million
Blueprint Medicines Corp expected to post a loss of $2.67 a share - Earnings Preview
Blueprint Medicines gains as FDA lifts partial hold on cancer drug trial
Brief: Blueprint Medicines Announces Lift Of Partial Clinical Hold On Phase 1/2 Vela Trial Of Blu-222
ORIC Pharma rises as H.C.Wainwright upgrades to 'buy' on cancer drug potential
U.S. RESEARCH ROUNDUP-Chart Industries, Nvidia, Seagen
Blueprint Medicines up on positive trial data for bone-marrow disease drug
Brief: Blueprint Medicines Presents Registrational Data From Pioneer Trial Of Ayvakit
U.S. RESEARCH ROUNDUP-C4 Therapeutics, Nvidia, WW Grainger
Brief: Blueprint Medicines To Regain Global Rights To GAVRETO (Pralsetinib) From Roche
U.S. RESEARCH ROUNDUP- Crocs, Equinix, Hubspot
U.S. RESEARCH ROUNDUP- Crocs, Equinix, Hubspot